{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:48:30Z","timestamp":1788961710363,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:00:00Z","timestamp":1715472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:00:00Z","timestamp":1715472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treating cancer-associated venous thromboembolism (CAT) with anticoagulation prevents recurrent venous thromboembolism (rVTE), but increases bleeding risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare incidence of rVTE, major bleeding, and all-cause mortality for rivaroxaban versus low molecular weight heparin (LMWH) in patients with CAT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a cohort study using Swedish national registers 2013\u20132019. Patients with CAT (venous thromboembolism within 6 months of cancer diagnosis) were included. Those with other indications or with high bleeding risk cancers were excluded (according to guidelines). Follow-up was from index-CAT until outcome, death, emigration, or end of study. Incidence rates (IR) per 1000 person-years with 95% confidence interval (CI) and propensity score overlap-weighted hazard ratios (HRs) for rivaroxaban versus LMWH were estimated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 283 patients on rivaroxaban and 5181 on LMWH. The IR for rVTE was 68.7 (95% CI 40.0\u2013109.9) for rivaroxaban, compared with 91.6 (95% CI 81.9\u2013102.0) for LMWH, with adjusted HR 0.77 (95% CI 0.43\u20131.35). The IR for major bleeding was 23.5 (95% CI 8.6\u201351.1) for rivaroxaban versus 49.2 (95% CI 42.3\u201356.9) for LMWH, with adjusted HR 0.62 (95% CI 0.26\u20131.49). The IR for all-cause mortality was 146.8 (95% CI 103.9\u2013201.5) for rivaroxaban and 565.6 (95% CI 541.8\u2013590.2) for LMWH with adjusted HR 0.48 (95% CI 0.34\u20130.67).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Rivaroxaban performed similarly to LMWH for patients with CAT for rVTE and major bleeding. An all-cause mortality benefit was observed for rivaroxaban which potentially may be attributed to residual confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT05150938 (Registered 9 December 2021).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11239-024-02992-1","type":"journal-article","created":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T10:01:18Z","timestamp":1715508078000},"page":"973-983","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-2189","authenticated-orcid":false,"given":"Marie","family":"Linder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ekbom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Brobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Vogtl\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanina","family":"Balabanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes Y. Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Psaroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abdelgawwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Hernan","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,12]]},"reference":[{"issue":"3","key":"2992_CR1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana AA et al (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632\u2013634","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2992_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/00005792-199909000-00001","volume":"78","author":"N Levitan","year":"1999","unstructured":"Levitan N et al (1999) Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Med (Baltim) 78(5):285\u2013291","journal-title":"Med (Baltim)"},{"key":"2992_CR3","unstructured":"WHO. Cancer (2023) 18 May 2023; https:\/\/www.who.int\/health-topics\/cancer#tab=tab_1"},{"issue":"1","key":"2992_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1186\/s12885-017-3719-1","volume":"17","author":"UT Khan","year":"2017","unstructured":"Khan UT et al (2017) Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis. BMC Cancer 17(1):747","journal-title":"BMC Cancer"},{"key":"2992_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4137\/CMO.S18991","volume":"8","author":"G Elyamany","year":"2014","unstructured":"Elyamany G, Alzahrani AM, Bukhary E (2014) Cancer-associated thrombosis: an overview. Clin Med Insights Oncol 8:129\u2013137","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"2992_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1160\/TH15-08-0686","volume":"117","author":"AT Cohen","year":"2017","unstructured":"Cohen AT et al (2017) Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 117(1):57\u201365","journal-title":"Thromb Haemost"},{"issue":"10","key":"2992_CR7","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","volume":"20","author":"D Farge","year":"2019","unstructured":"Farge D et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566\u2013e581","journal-title":"Lancet Oncol"},{"issue":"4","key":"2992_CR8","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH et al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927\u2013974","journal-title":"Blood Adv"},{"issue":"9","key":"2992_CR9","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/jth.14219","volume":"16","author":"AA Khorana","year":"2018","unstructured":"Khorana AA et al (2018) Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 16(9):1891\u20131894","journal-title":"J Thromb Haemost"},{"key":"2992_CR10","doi-asserted-by":"crossref","unstructured":"Fernandes CJ et al (2019) Cancer-associated thrombosis: the when, how and why. Eur Respiratory Rev, 28(151)","DOI":"10.1183\/16000617.0119-2018"},{"key":"2992_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","volume":"173","author":"A Li","year":"2019","unstructured":"Li A et al (2019) Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res 173:158\u2013163","journal-title":"Thromb Res"},{"issue":"20","key":"2992_CR12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 36(20):2017\u20132023","journal-title":"J Clin Oncol"},{"key":"2992_CR13","doi-asserted-by":"crossref","unstructured":"Alzghari S et al (2017) Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: the Re-CLOT study. J Oncol Pharm Pract","DOI":"10.1177\/1078155217718382"},{"issue":"11","key":"2992_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/ajh.25604","volume":"94","author":"WE Wysokinski","year":"2019","unstructured":"Wysokinski WE et al (2019) Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol 94(11):1185\u20131192","journal-title":"Am J Hematol"},{"issue":"5","key":"2992_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ajh.25059","volume":"93","author":"MB Streiff","year":"2018","unstructured":"Streiff MB et al (2018) Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol 93(5):664\u2013671","journal-title":"Am J Hematol"},{"key":"2992_CR16","first-page":"107602962094004","volume":"27","author":"MFH Mohamed","year":"2021","unstructured":"Mohamed MFH et al (2021) The net clinical benefit of rivaroxaban compared to low-molecular-weight heparin in the treatment of cancer-associated thrombosis: systematic review and meta-analysis. Clin Appl Thromb Hemost 27:1076029620940046","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"2992_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.21037\/atm-20-8156","volume":"9","author":"X Song","year":"2021","unstructured":"Song X et al (2021) Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs). Ann Transl Med 9(2):162","journal-title":"Ann Transl Med"},{"issue":"2","key":"2992_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaccao.2022.10.014","volume":"5","author":"CI Coleman","year":"2023","unstructured":"Coleman CI et al (2023) Effectiveness and safety of rivaroxaban and low molecular weight heparin in cancer-associated venous thromboembolism. JACC CardioOncol 5(2):189\u2013200","journal-title":"JACC CardioOncol"},{"issue":"1","key":"2992_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/02841860802247664","volume":"48","author":"L Barlow","year":"2009","unstructured":"Barlow L et al (2009) The completeness of the Swedish Cancer Register: a sample survey for year 1998. Acta Oncol 48(1):27\u201333","journal-title":"Acta Oncol"},{"key":"2992_CR20","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF et al (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450","journal-title":"BMC Public Health"},{"issue":"7","key":"2992_CR21","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B et al (2007) The new Swedish prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726\u2013735","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2992_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF et al (2016) Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 31(2):125\u2013136","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"2992_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL et al (2017) The Swedish cause of death register. Eur J Epidemiol 32(9):765\u2013773","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"2992_CR24","first-page":"250","volume":"188","author":"F Li","year":"2019","unstructured":"Li F, Thomas LE, Li F (2019) Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 188(1):250\u2013257","journal-title":"Am J Epidemiol"},{"issue":"408","key":"2992_CR25","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","volume":"84","author":"DY Lin","year":"1988","unstructured":"Lin DY, Wei LJ (1988) The robust inference for the Cox proportional hazards model. J Am Stat Assoc 84(408):1074\u20131078","journal-title":"J Am Stat Assoc"},{"issue":"446","key":"2992_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94(446):496\u2013509","journal-title":"J Am Stat Assoc"},{"issue":"17","key":"2992_CR27","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1182\/bloodadvances.2020002242","volume":"4","author":"OS Costa","year":"2020","unstructured":"Costa OS et al (2020) Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. Blood Adv 4(17):4045\u20134051","journal-title":"Blood Adv"},{"issue":"7","key":"2992_CR28","doi-asserted-by":"publisher","first-page":"e2325283","DOI":"10.1001\/jamanetworkopen.2023.25283","volume":"6","author":"IB Riaz","year":"2023","unstructured":"Riaz IB et al (2023) Comparative effectiveness of anticoagulants in patients with Cancer-Associated thrombosis. JAMA Netw Open 6(7):e2325283","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2992_CR29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.21873\/invivo.11845","volume":"34","author":"JH Kim","year":"2020","unstructured":"Kim JH et al (2020) Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in advanced upper gastrointestinal tract and hepatopancreatobiliary cancer. Vivo 34(2):829\u2013837","journal-title":"Vivo"},{"issue":"1","key":"2992_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12959-022-00399-7","volume":"20","author":"T Rungjirajittranon","year":"2022","unstructured":"Rungjirajittranon T et al (2022) Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis. Thromb J 20(1):41","journal-title":"Thromb J"},{"issue":"3","key":"2992_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000499895","volume":"98","author":"JH Lee","year":"2019","unstructured":"Lee JH et al (2019) A retrospective study on efficacy and safety of rivaroxaban and dalteparin for long-term treatment of venous thromboembolism in patients with lung cancer. Respiration 98(3):203\u2013211","journal-title":"Respiration"},{"issue":"1","key":"2992_CR32","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.3802\/jgo.2020.31.e10","volume":"31","author":"JH Lee","year":"2020","unstructured":"Lee JH et al (2020) Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers. J Gynecol Oncol 31(1):e10","journal-title":"J Gynecol Oncol"},{"key":"2992_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.thromres.2019.02.031","volume":"177","author":"MC Vedovati","year":"2019","unstructured":"Vedovati MC, Giustozzi M, Becattini C (2019) Venous thromboembolism and cancer: current and future role of direct-acting oral anticoagulants. Thromb Res 177:33\u201341","journal-title":"Thromb Res"},{"issue":"3","key":"2992_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","volume":"161","author":"B Planquette","year":"2022","unstructured":"Planquette B et al (2022) Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 161(3):781\u2013790","journal-title":"Chest"},{"issue":"1","key":"2992_CR35","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/jth.15153","volume":"19","author":"JK Schaefer","year":"2021","unstructured":"Schaefer JK et al (2021) Anticoagulant medication adherence for cancer-associated thrombosis: a comparison of LMWH to DOACs. J Thromb Haemost 19(1):212\u2013220","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2992_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/sim.4780100409","volume":"10","author":"H Petri","year":"1991","unstructured":"Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10(4):577\u2013581","journal-title":"Stat Med"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02992-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02992-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02992-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T08:05:29Z","timestamp":1723190729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02992-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,12]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["2992"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02992-1","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,12]]},"assertion":[{"value":"26 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ML, DHG, and AE report participation in research projects funded by Bayer AG and other pharmaceutical companies, all regulator-mandated phase IV-studies, all with funds paid to the institution where they were employed (no personal fees). CB reports consulting fees and honoraria from Bayer AG, consulting fees and honoraria from Bristol Myers Squibb, consulting fees and honoraria from Daiichi Sankyo, and consulting fees from Pfizer. KV, YB, GP, KA, MR, and BS are employees of Bayer AG, or were employees at the time of data generation\/manuscript preparation. MC reports grants and consulting fees from Pfizer, grants and consulting fees from LEO Pharma, grants and consulting fees from Bristol Myers Squibb, consulting fees from Bayer AG, consulting fees from Sanofi, and consulting fees from Servier. ATC reports grants, consulting fees and honoraria from Alexion\/AstraZeneca, grants, consulting fees and honoraria from Bristol Myers Squibb\/Pfizer, and consulting fees and honoraria from Bayer AG. CIC reports grants, consulting fees and travel support from Bayer AG, grants and consulting fees from Janssen Pharmaceuticals, grants and consulting fees from Alexion Pharmaceutical, and honoraria from Medscape. AAKa reports consulting fees, honoraria and travel support from Bayer AG, consulting fees, honoraria and travel support from Janssen, consulting fees and honoraria from Bristol Myers Squibb, consulting fees and honoraria from Anthos, consulting fees and honoraria from Pfizer, consulting fees and honoraria from Sanofi, and honoraria from WebMD. AYYL reports consulting fees and honoraria from Bayer AG, consulting fees and honoraria from LEO Pharma, consulting fees and honoraria from Pfizer, consulting fees from Servier and honoraria from Bristol Myers Squibb. GB is a consultant to Bayer AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}